Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24

Articles

19391 items
12:00 AM, Oct 25, 1993  |  BioCentury | Product Development

Where Tanox will take its HIV program

After languishing for almost two years,Tanox Biosystems Inc.'s anti-HIV monoclonal antibodies have been returned to the company by partner Ciba-Geigy Ltd. Ciba completed a Phase I/II Swiss trial in 12 late-stage AIDS patients in October...
12:00 AM, Oct 25, 1993  |  BioCentury | Strategy

Speedy development drives Magainin strategy

Speedy development drives Magainin strategy Magainin Pharmaceuticals Inc., one of a growing number of biotech companies taking a new look at the antibiotics market, has sought to lower its risk by systematically focusing itself on...
12:00 AM, Oct 25, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Creative BioMolecules Inc. Robert Fine of Nomura Equity Research initiated coverage of Creative BioMolecules Inc. with a "buy." He said CBMI shares have a fair value of $11 and he has a one-year price target of...
12:00 AM, Oct 25, 1993  |  BioCentury | Finance

Sizing up Neozyme's returns

Investors in Genzyme Corp.'s Neozyme I special purpose corporation will get an annualized pre-tax return on investment exceeding 30 percent, following GENZ's announcement last week that it will buy back the rights and technology to...
12:00 AM, Oct 25, 1993  |  BioCentury | Politics, Policy & Law

Incentives to prove cost-benefit

WASHINGTON - Concerted efforts to induce companies to conduct rigorous pharmacoeconomic research on new products in addition to safety and efficacy studies have begun to emerge from industry and Capitol Hill. Rep. Ron Wyden, D-Ore.,...
12:00 AM, Oct 18, 1993  |  BioCentury | Product Development

Panorex study whets appetite for more data

After five years, Centocor Inc. presented encouraging findings from its study of the Panorex monoclonal antibody in colorectal cancer, but indications are that both the company and clinicians will want to see the results replicated...
12:00 AM, Oct 18, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Vertex Pharmaceuticals Inc. (VRTX) Robertson, Stephens analyst Michael Walsh initiated coverage with a "strong buy." Within three years, Walsh said, the rational drug design company could file four NDAs for indications that are all candidates...
12:00 AM, Oct 18, 1993  |  BioCentury | Regulation

The FDA's word on cell and gene therapies

The FDA announced in an article published in the current New England Journal of Medicine that the agency will apply existing regulations to somatic-cell therapy and gene therapies. Industry representatives were pleased but not...
12:00 AM, Oct 18, 1993  |  BioCentury | Politics, Policy & Law

Decreasing dependency on research grants

Although the research deal between Scripps Research Institute and Sandoz Pharmaceuticals Corp. generated a great deal of negative publicity this year, it is a fact of life that all non-profit organizations must worry about maintaining...
12:00 AM, Oct 18, 1993  |  BioCentury | Politics, Policy & Law

Rifle shot

Rifle shot Sen. John Chafee, architect of a Republican alternative to the Clinton health care plan, last week exhorted an assembly of biotech CEOs to confront the specter of price controls head on. According to...

Pages